Centrophenoxin
Cas No.: 51-68-3
What is centrophenoxine?
Centrophenoxine (meclofenoxate) is a substance formed from the combination of two other compounds, DMAE (dimethylaminoethanol) and pCPA (para-chlorophenoxyacetic acid). DMAE on its own does not have the free ability to cross the blood-brain barrier, but with the right combination in centrophenoxine, it becomes an excellent choline carrier and has a stimulating effect on brain function.
Other names under which this compound can be found are clofenoxate, meclopenoxate, clofenoxin, prozeryl, 4- (dimethylamino) ethyl 2- (2-chlorophenoxy) acetate. The preparation is sold under the name Lucidril as a nootropic agent.
Use of centrophenoxine
The product is used to stimulate brain function and increase its efficiency. Centrophenoxine exhibits nootropic effects, meaning that it improves cognitive function, enhances learning and mental work processes. It has a beneficial effect on memory and concentration, and ensures more efficient processing of information.
Because the compound can reduce the accumulation of beta amyloid and lipofuxin in brain cells, it minimizes the risk of developing certain neurodegenerative diseases. It can also alleviate symptoms of dementia in the elderly.
Mechanism of action
The most important mechanism of action of centrophenoxine comes down to the supply of choline to the central nervous system. In addition, the compound may inhibit choline utilization by peripheral tissues. Choline is a precursor for the synthesis of one of the most important neurotransmitters – acetylcholine. In addition, centrophenoxine stimulates the metabolic activity of brain cells, increasing glucose and oxygen utilization. The compound also exhibits antioxidant activity. Thus, it can slow down neurodegenerative processes and brain aging.
Centrophenoxine – dosage
The recommended dosage is 500-1000 mg per day. You can divide such an amount, for example, into 2-3 doses of 250 mg each. To increase the effectiveness of the product, it can be taken together with aniracetam or Noopept.
References:
- Fülöp T Jr, Wórum I, Csongor J, Leövey A, Szabó T, Pék G, Zs -Nagy I. Effects of centrophenoxine on body composition and some biochemical parameters of demented elderly people as revealed in a double-blind clinical trial. Arch Gerontol Geriatr. 1990 May-Jun;10(3):239-51; https://pubmed.ncbi.nlm.nih.gov/15374499/
- Ludwig-Festl M, Gräter B, Bayreuther K. Erhöhung von Zellstoffwechselleistungen in normalen, diploiden, menschlichen Glia-Zellen in stationären Zellkulturen induziert durch Meclofenoxat [Increase in cell metabolism in normal, diploid human glial cells in stationary cell cultures induced by meclofenoxate]. Arzneimittelforschung. 1983;33(4):495-501; https://pubmed.ncbi.nlm.nih.gov/6191765/
- Sharma D, Singh R. Centrophenoxine activates acetylcholinesterase activity in hippocampus of aged rats. Indian J Exp Biol. 1995 May;33(5):365-8; https://pubmed.ncbi.nlm.nih.gov/7558197/
- Nandy K. Centrophenoxine: effects on aging mammalian brain. J Am Geriatr Soc. 1978 Feb;26(2):74-81; https://pubmed.ncbi.nlm.nih.gov/342588/
